TWI839690B - 治療黑色素瘤的藥物組合的用途 - Google Patents

治療黑色素瘤的藥物組合的用途 Download PDF

Info

Publication number
TWI839690B
TWI839690B TW111106633A TW111106633A TWI839690B TW I839690 B TWI839690 B TW I839690B TW 111106633 A TW111106633 A TW 111106633A TW 111106633 A TW111106633 A TW 111106633A TW I839690 B TWI839690 B TW I839690B
Authority
TW
Taiwan
Prior art keywords
melanoma
inhibitor
anticancer agent
compound
cdk inhibitor
Prior art date
Application number
TW111106633A
Other languages
English (en)
Chinese (zh)
Other versions
TW202233177A (zh
Inventor
維納 阿葛瓦爾
葛瑞得哈倫 派瑞亞沙米
瑪基 喬伊斯 拉瑟斯
安基塔 斯里瓦斯塔瓦
蘇里薩 錫里尼娃撒
Original Assignee
印度商皮拉馬爾企業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 印度商皮拉馬爾企業有限公司 filed Critical 印度商皮拉馬爾企業有限公司
Publication of TW202233177A publication Critical patent/TW202233177A/zh
Application granted granted Critical
Publication of TWI839690B publication Critical patent/TWI839690B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111106633A 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合的用途 TWI839690B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845749P 2013-07-12 2013-07-12
US61/845,749 2013-07-12

Publications (2)

Publication Number Publication Date
TW202233177A TW202233177A (zh) 2022-09-01
TWI839690B true TWI839690B (zh) 2024-04-21

Family

ID=52279411

Family Applications (4)

Application Number Title Priority Date Filing Date
TW111106633A TWI839690B (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合的用途
TW103123951A TWI680760B (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合
TW108142557A TW202031253A (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合
TW113110009A TW202502325A (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW103123951A TWI680760B (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合
TW108142557A TW202031253A (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合
TW113110009A TW202502325A (zh) 2013-07-12 2014-07-11 治療黑色素瘤的藥物組合的用途

Country Status (12)

Country Link
US (4) US11007174B2 (enExample)
EP (1) EP3019166B1 (enExample)
JP (5) JP6568060B2 (enExample)
CN (3) CN105530931B (enExample)
AR (1) AR096892A1 (enExample)
AU (1) AU2014288857B2 (enExample)
CA (1) CA2917742C (enExample)
DK (1) DK3019166T3 (enExample)
ES (1) ES2733929T3 (enExample)
IL (1) IL243572B (enExample)
TW (4) TWI839690B (enExample)
WO (1) WO2015004636A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3019166T3 (da) 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
IL274663B2 (en) 2017-11-17 2024-01-01 Univ Illinois Cancer therapy by degrading dual mek signaling
CN107827726B (zh) * 2017-11-28 2020-09-15 辽宁中医药大学 马齿苋中化合物Oleracone E及其提取分离方法
CN108591464B (zh) * 2018-06-28 2020-06-23 宁波奥克斯高科技有限公司 一种气体绝缘开关柜用密封结构
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
MX2021012248A (es) * 2019-04-11 2022-03-11 Mei Pharma Inc Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN112168821B (zh) * 2020-11-09 2022-10-14 中南大学湘雅医院 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用
WO2022109307A1 (en) * 2020-11-19 2022-05-27 Mei Pharma, Inc. Treatment of kras mutant cancers
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179210A1 (en) * 2006-06-21 2010-07-15 Meenakshi Sivakumar Novel enantiomerically pure compounds for the treatment of proliferative disorders
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
AU2001242629B2 (en) 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
US6683095B2 (en) 2000-05-03 2004-01-27 Lg Life Sciences Ltd. CDK inhibitors having 3-hydroxychromen-4-one structure
IL153688A0 (en) 2000-06-28 2003-07-06 Teva Pharma Carvedilol
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
AU2003276453A1 (en) 2002-11-06 2004-06-07 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
CN1889943A (zh) 2003-12-08 2007-01-03 美国亚利桑那大学董事会 协同抗癌组合物
AU2006223257A1 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
MX2009000109A (es) 2006-07-07 2009-03-16 Piramal Life Sciences Ltd Sintesis enantioselectiva de pirrolidinas sustituidas con flavonas y de sus intermediarios.
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
ATE538652T1 (de) 2007-05-15 2012-01-15 Piramal Life Sciences Ltd Synergistische pharmazeutische kombination für die behandlung von krebs
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
KR20130027476A (ko) 2010-02-26 2013-03-15 피라말 엔터프라이지즈 리미티드 염증 질환을 치료하기 위한 피롤리딘으로 치환된 플라본
CN101841463B (zh) * 2010-03-05 2012-05-16 清华大学 基于sctp的多路径并发传输方法
EP2608790A4 (en) * 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
WO2012068468A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
AU2011330733A1 (en) 2010-11-19 2013-06-06 Piramal Enterprises Limited Pharmaceutical combination of paclitaxel and a CDK inhibitor
WO2012123889A1 (en) * 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
KR20140056227A (ko) 2011-06-24 2014-05-09 피라말 엔터프라이지즈 리미티드 인간 유두종바이러스와 관련된 암의 치료를 위한 화합물
IN2014MN01546A (enExample) 2012-01-13 2015-05-08 Piramal Entpr Ltd
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2014128523A1 (en) 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
DK3019166T3 (da) 2013-07-12 2019-07-29 Piramal Entpr Ltd A Pharmaceutical Combination for the Treatment of Melanoma
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179210A1 (en) * 2006-06-21 2010-07-15 Meenakshi Sivakumar Novel enantiomerically pure compounds for the treatment of proliferative disorders
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Tharcísio Citrângulo Tortelli Junior,et al. ."Abstract 5598: Interaction between BRAF inhibitor PLX-4720 and CDK inhibitors can sensitize melanoma cells with BRAF V600E mutation", AACR 103rd Annual Meeting, 2012‐‐ Mar 31‐ Apr 4, 2012, Published April 2012; Abstract 5598; https://cancerres.aacrjournals. Org /content/ 72 / 8_Supplement/5598. *

Also Published As

Publication number Publication date
CN111053768A (zh) 2020-04-24
CN105530931A (zh) 2016-04-27
EP3019166A4 (en) 2017-04-19
IL243572A0 (en) 2016-02-29
TW202233177A (zh) 2022-09-01
JP2019206565A (ja) 2019-12-05
CA2917742A1 (en) 2015-01-15
AU2014288857A1 (en) 2016-02-04
TW201534297A (zh) 2015-09-16
WO2015004636A1 (en) 2015-01-15
CA2917742C (en) 2020-04-14
US11007174B2 (en) 2021-05-18
JP7799508B2 (ja) 2026-01-15
US20160136132A1 (en) 2016-05-19
JP2021001186A (ja) 2021-01-07
CN117731786A (zh) 2024-03-22
US11839591B2 (en) 2023-12-12
US12383530B2 (en) 2025-08-12
JP2022068335A (ja) 2022-05-09
JP2016525097A (ja) 2016-08-22
AU2014288857B2 (en) 2019-03-14
CN105530931B (zh) 2019-11-08
US20240165076A1 (en) 2024-05-23
CN111053768B (zh) 2023-12-12
US20190282544A1 (en) 2019-09-19
TW202031253A (zh) 2020-09-01
EP3019166A1 (en) 2016-05-18
EP3019166B1 (en) 2019-05-08
DK3019166T3 (da) 2019-07-29
JP6568060B2 (ja) 2019-08-28
JP2024037891A (ja) 2024-03-19
AR096892A1 (es) 2016-02-03
TWI680760B (zh) 2020-01-01
IL243572B (en) 2019-10-31
US20210393589A1 (en) 2021-12-23
ES2733929T3 (es) 2019-12-03
TW202502325A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
US12383530B2 (en) Pharmaceutical combination for the treatment of melanoma
US20200206188A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
TWI743019B (zh) 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
TW202210076A (zh) 組合療法
KR20240051953A (ko) Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법
US20220087991A1 (en) Nlrp3 modulators
HK40102341A (zh) 用於治疗黑素瘤的药物组合
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
US20200061054A1 (en) Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor
JP2007505859A (ja) イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置
HK1224936B (en) A pharmaceutical combination for the treatment of melanoma
HK1224936A1 (en) A pharmaceutical combination for the treatment of melanoma
WO2026015745A1 (en) Macrocyclic ras inhibitors
BR112024002063B1 (pt) Compostos que inibem isoforma alfa de pi3k, composições que o compreendem, usos dos mesmos, e combinações